New Launch13 Jun 2026, 01:30 pm
Dr. Reddy's Launches Generic Bosutinib Tablets 400mg in US
AI Summary
Dr. Reddy's Laboratories has announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. This launch expands the company's oncology portfolio and aims to improve patient access to affordable medicines. The product is a first-to-file generic eligible for 180-day exclusivity. Dr. Reddy's holds exclusive marketing rights, while MSN Laboratories developed and manufactured the product. The Bosulif® brand had U.S. sales of approximately $253.8 million for the 12 months ended April 2026.
Key Highlights
- Dr. Reddy's launched generic Bosutinib Tablets 400mg in the US.
- This is a first-to-market and first-to-file generic product.
- The launch expands Dr. Reddy's oncology portfolio.
- The product is eligible for 180-day generic drug exclusivity.
- Bosulif® brand had US sales of $253.8 million in the prior 12 months.
Price Impact
More from DRREDDY